(NASDAQ: NEUP) Neuphoria Therapeutics's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 16.2%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 34.65%.
Neuphoria Therapeutics's earnings in 2026 is -$12,450,808.On average, 4 Wall Street analysts forecast NEUP's earnings for 2026 to be -$30,705,416, with the lowest NEUP earnings forecast at -$37,445,972, and the highest NEUP earnings forecast at -$23,096,349. On average, 4 Wall Street analysts forecast NEUP's earnings for 2027 to be -$21,416,614, with the lowest NEUP earnings forecast at -$28,283,096, and the highest NEUP earnings forecast at -$13,789,712.
In 2028, NEUP is forecast to generate -$18,853,236 in earnings, with the lowest earnings forecast at -$23,198,495 and the highest earnings forecast at -$13,959,955.